MELANOMA INSTITUTE AUSTRALIA
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
- Conditions
- Melanoma Metastatic
- Interventions
- Drug: Immunotherapy alone
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 129
- Registration Number
- NCT06767306
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Personalised Immunotherapy Platform
- Conditions
- Basal Cell CarcinomaSolid TumorMelanomaCutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma
- Interventions
- Other: Predictive model
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 1000
- Registration Number
- NCT06536257
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
🇦🇺Melanoma Institute Australia, Sydney, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT06288191
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
- Conditions
- Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT06151236
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Melanoma Institute Australia
- Registration Number
- NCT05545969
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
- Conditions
- Stage II Melanoma
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT05418972
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
- Conditions
- Melanoma Stage III
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 21
- Registration Number
- NCT04207086
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
- Conditions
- In-Transit Metastasis of Cutaneous MelanomaMelanoma
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Melanoma Institute Australia
- Registration Number
- NCT03754140
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
- Conditions
- Basal Cell CarcinomaBasal Cell Carcinoma of Skin, Site UnspecifiedInvasive CarcinomaSkin Cancer
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT03534947
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- Conditions
- Melanoma Stage Iv
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 218
- Registration Number
- NCT03340129
- Locations
- 🇦🇺
Sir Charles Gairdner Hosptial, Perth, Western Australia, Australia
🇸🇪Skåne University Hospital, Lund, Skane, Sweden
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia